New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:25 EDTNBIXNeurocrine receives Breakthrough Therapy Designation for dyskinesia candidate
Subscribe for More Information
October 20, 2014
16:07 EDTNBIXNeurocrine initiates Phase III study for VMAT2 Inhibitor NBI-98854
Subscribe for More Information
October 17, 2014
07:24 EDTNBIXNeurocrine management to meet with Deutsche Bank
Meeting to be held in Los Angeles on October 17 hosted by Deutsche Bank.
October 16, 2014
07:12 EDTNBIXNeurocrine management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use